DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
73.43
+1.89 (2.64%)
Jul 27, 2026, 12:04 PM EDT - Market open

Company Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.

The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.

It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom, Inc.
DexCom logo
CountryUnited States
Founded1999
IPO DateApr 14, 2005
IndustryMedical Devices
SectorHealthcare
Employees11,100
CEOJacob Leach

Contact Details

Address:
6340 Sequence Drive
San Diego, California 92121
United States
Phone858 200 0200
Websitedexcom.com

Stock Details

Ticker SymbolDXCM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001093557
CUSIP Number252131107
ISIN NumberUS2521311074
Employer ID33-0857544
SIC Code3841

Key Executives

NamePosition
Jacob Steven LeachPresident, Chief Executive Officer and Director
Kevin Ronald SayerExecutive Chairman of the Board
Jereme M. Sylvain CPAExecutive Vice President, Chief Financial Officer and Chief Accounting Officer
Michael Jon Brown J.D.Executive Vice President, Chief Legal and Compliance Officer
Sadie M. SternExecutive Vice President, Chief People and Culture Officer
Jon ColemanExecutive Vice President and Chief Commercial Officer
Peter SimpsonExecutive Vice President and Chief Technology Officer
Sean ChristensenVice President of Finance and Investor Relations
Matthew DolanExecutive Vice President of Strategy and Corporate Development

Latest SEC Filings

DateTypeTitle
Jul 20, 2026144Filing
Jul 15, 2026144Filing
Jul 6, 2026144Filing
Jun 15, 2026144Filing
Jun 15, 2026144Filing
Jun 4, 2026144Filing
Jun 3, 2026144Filing
May 28, 20268-KCurrent Report
May 28, 2026SDForm - SD
May 21, 2026144Filing